-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $41

Benzinga·04/02/2026 12:14:42
Listen to the news
Mizuho analyst Graig Suvannavejh maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and raises the price target from $20 to $41.